Hi All, some great information & posts over the last few days &...

Hi All, some great information & posts over the last few days & welcome to @lalitha12 if you decide to invest in IMU & just to let you know I am also invested in Actinogen & hence don’t have investor biase, it’s not appropriate to discuss that here, so pop over there for that information & read everything pertinent on both stocks, ASX announcements & both Biotechs have twitter accounts to keep up with information. There’s more going on & I’m very keen on both companies, albeit AD is a massive risk with above 90% failure rate including MAbs recently. Cortisol theory is very interesting & new indications & Ph2 recently done & clearly we are all looking forward to that.

Back to Imugene (IMU),

@Justglenn1 I agree with you. MABs targeting T cells are not for everyone. The cardiac toxicity is a worry especially for older patients, but when you have no other option??. Some side effects are a given in cancer treatment & we know that with chemo.

What really interests me here, & even Pfizer quotes in the article, are more treatment options available to oncologists, & combination therapy is really something Leslie Chong has been hitting home with in a message & this is a big question here...how would B cell & Existing T cell MABs go with efficacy & safety in clinical trials? 2 different cell types in an immune response in targeting PD1 receptors? Would B cell vaccines allow a greater degree of efficacy to assist T cell vaccines in a mounted immune response with 2 different cell types within our immune system?

Will B cell vaccines be looked at seriously by Big Pharmas & Oncologists when patients have a contraindication or very poor prognosis with MABs? Phase 2 will be telling plus extended data from 1b & heading into Ph2. Really love to see a collaboration to increase trial sizes. I was actually more excited about this press article seeing Pfizer are targeting Her-2 Receptor cancers in Breast & Gastric Cancer, than a negative & one more drug on the market. x